SCHEMBL23529337

SCHEMBL23529337

COc1c(C(N)=O)ccc2c1nc(-c1c(F)cc(F)cc1-c1n[nH]c(=O)o1)n2CCn1c(-c2c(F)cc(F)cc2-c2n[nH]c(=O)o2)nc2c(OC)c(C(N)=O)ccc21

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 7/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CHRM2 P08172 5/20 0.33
CHRM1 P11229 5/20 0.33
RRM1 P23921 5/20 0.33
RRM2B Q7LG56 5/20 0.33
PARP1 P09874 1/20 0.33
NOTUM Q6P988 2/20 0.33
PKN1 Q16512 1/20 0.33
PKN2 Q16513 1/20 0.33
CTSD P07339 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29948206 1.00 PTGER4 (0.33) PTGER4KDM4EALDH1A1GLAHSD17B10
SCHEMBL23529326 0.93 RRM1 (0.36) CHRM2CHRM1RRM1RRM2BNOTUM
SCHEMBL29948192 0.93 RRM1 (0.36) CHRM2CHRM1RRM1RRM2BNOTUM
SCHEMBL29948137 0.89 NOTUM (0.40) PTGER4KDM4EALDH1A1GLAHSD17B10
SCHEMBL23529308 0.89 NOTUM (0.40) PTGER4KDM4EALDH1A1GLAHSD17B10
SCHEMBL24801625 0.82 NOTUM (0.44) PTGER4KDM4EALDH1A1GLAHSD17B10
SCHEMBL29948143 0.82 NOTUM (0.44) PTGER4KDM4EALDH1A1GLAHSD17B10
SCHEMBL23529314 0.82 GPR35 (0.36) PTGER4PARP1PKN1PKN2
SCHEMBL29948208 0.82 GPR35 (0.36) PTGER4PARP1PKN1PKN2
SCHEMBL23529303 0.81 PTGER4 (0.41) PTGER4PKN1PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US claimed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP claimed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US claimed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US claimed
CN-114981265-A Compound (I) CTXT私人有限公司 2022-08-30 CN claimed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO claimed
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO disclosed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS PTGER4 2061/4885KDM4E 3167/4885ALDH1A1 4610/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS PTGER4 1426/4885KDM4E 3370/4885ALDH1A1 4143/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS PTGER4 1526/4885KDM4E 3952/4885ALDH1A1 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.